Pharmaceutical composition containing leuprolide and having both immediate and sustained release properties
The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.
1. A method for preparing a pharmaceutical composition, the method comprising the steps of:
(a) preparing an immediate release part comprising leuprolide as a first active ingredient;
(b) preparing a sustained release part comprising leuprolide contained in a microsphere as a second active ingredient, wherein the microsphere is prepared by the steps of:
(i) mixing an inner aqueous phase (W1) containing leuprolide, a thickener and an aqueous solvent with an oil phase (O) containing a polymer and a fat-soluble solvent to obtain a W1/O emulsion;
(ii) dispersing the W1/O emulsion of step (i) in a polyvinyl alcohol aqueous solution (W2) to obtain a W1/O/W2 emulsion; and
(iii) drying and recovering the W1/O/W2 emulsion prepared in step (ii); and
(c) mixing the immediate release part and the sustained release part in a pharmaceutically acceptable carrier to form a pharmaceutical composition, wherein the immediate release part comprises 0.1% to 20% of a total amount of leuprolide in the pharmaceutical composition and wherein the microsphere of the sustained release part comprises 80% to 99.9% of the total amount of leuprolide in the pharmaceutical composition; and wherein the ratio of leuprolide in the immediate release part to leuprolide in the microsphere of the sustained release part is determined to achieve both immediate and sustained release properties.
2. The method of claim 1 , wherein Time to Peak Plasma Concentration (Tmax) of the composition is 50 to 70 minutes.
3. The method of claim 1 , wherein the duration of action of the active ingredients in the composition is four weeks or longer.
4. The method of claim 1 , wherein the thickener is selected from the group consisting of gelatin, albumin, pectin, agar, cellulose, dextrin, xanthan gum and mixtures thereof.
5. The method of claim 1 , wherein the polyvinyl alcohol aqueous solution of step (ii) contains 0.01 to 7% by weight of an osmotic pressure regulator, on the basis of a total weight of the composition.
6. The method of claim 5 , wherein the osmotic pressure regulator is selected from the group consisting of pentahydric alcohol, hexahydric alcohol, water-soluble monohydric alcohol, water-soluble monosaccharide, water-soluble disaccharide, water-soluble oligosaccharide or derivatives thereof, and water-soluble amino acid.